Abstract
Myopathy is a life-threatening disease that can be caused, among other things, by the intake of various medications. Despite the fact that many drug-induced myopathies are well known, however, many health professionals are not alert to myopathies caused by drug interactions. Myopathy is a wellknown adverse reaction of statins, and muscle damage can range from minor muscle pain and weakness to life-threatening rhabdomyolysis. Colchicine can also cause myopathy, including rhabdomyolysis. The combination of colchicine and statins can significantly increase the risk of myopathy compared with their intake separately. In cases of development of myopathy in patients receiving colchicine and statins simultaneously, the most common manifestation of drug interaction was muscle weakness, occurring in almost every case, and in some cases, muscle weakness was so severe that the patient lost the ability to move. In a third of cases, the development of muscle weakness was accompanied by muscular pain, and darkening of urine to tea shade. One study showed that 40 % of patients received concurrent combinations of drugs that increased the risk of muscle damage. It is concluded that the simultaneous administration of colchicine and statins requires an assessment of the “benefit-risk” ratio, as well as the administration of drugs in minimally effective doses.
Highlights
Колхицин может также вызвать развитие миопатии, в том числе и развитие рабдомиолиза
Вызванные взаимодействием колхицина и статинов Myopathy Caused by the Interaction of Colchicine and Statins administration of colchicine and statins requires an assessment of the “benefit-risk” ratio, as well as the administration of drugs in minimally effective doses
Если пациентам все-таки необходимо одновременное назначение колхицина и статинов, необходимо провести оценку соотношения «польза–риск», назначать препараты в минимально эффективных дозах, проводить регулярный мониторинг состояния мышечной системы пациента и незамедлительно отменять применение препаратов при выявлении любых мышечных болей или мышечной слабости, а также при изменении показателей лабораторных анализов и цвета мочи
Summary
Колхицин может также вызвать развитие миопатии, в том числе и развитие рабдомиолиза. Как и в случае со статинами, повреждения мышц часто происходят, когда совместно принимаемые ингибиторы CYP3A4 вызывают значительное увеличение концентрации колхицина в плазме крови. Вызванные взаимодействием колхицина и статинов Myopathy Caused by the Interaction of Colchicine and Statins administration of colchicine and statins requires an assessment of the “benefit-risk” ratio, as well as the administration of drugs in minimally effective doses. Миопатия является хорошо известной нежелательной реакцией при применении статинов, при этом повреждение мышц может варьироваться от незначительной мышечной боли и слабости до угрожающего жизни рабдомиолиза
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
